Skip to main content

Table 1 Patient baseline characteristics, selection of the platinum agent, and hematological AE management of studied doublets

From: Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study

Platinum-based doublet Platinum/Pemetrexed Platinum/Docetaxel Platinum/Paclitaxel Platinum/Gemcitabine Platinum/Vinorelbine  
Sample size 517 248 322 450 309 P value*
Variables N Mean/% STDEV N Mean/% STDEV N Mean/% STDEV N Mean/% STDEV N Mean/% STDEV  
Demography                 
Age (years) 511 55.5 9.8 248 54.1 9.9 322 53.8 10.5 447 55.1 9.4 308 53.5 10.2 0.019
BMI 441 23.6 3.2 136 23.9 3.2 214 23.5 3.3 332 23.7 3.3 103 23.0 3.4 0.228
BSA (m2) 457 1.7 0.2 214 1.7 0.2 276 1.7 0.2 395 1.7 0.2 266 1.6 0.2 <0.001
Male (%) 303 58.6% 166 66.9% 194 60.3% 296 65.8% 187 60.5% 0.074
Non-smoking (%) 291 56.3% 107 43.2% 173 53.7% 211 46.9% 159 51.5% 0.003
Public health insurance plan (%)                 
Urban residents 307 59.4% 132 53.2% 166 51.6% 231 51.3% 132 42.7% <0.001
Rural residents 89 17.2% 65 26.2% 76 23.6% 108 24.0% 126 40.8% <0.001
ECOG performance status (%)                 
0 193 37.3% 58 23.4% 128 39.8% 133 29.6% 60 19.4% <0.001
1 304 58.8% 180 72.6% 190 59.0% 299 66.4% 237 76.7% <0.001
2 13 2.5% 9 3.6% 3 0.9% 13 2.9% 10 3.2% 0.265
Baseline marrow function                 
Hemoglobin (g/l) 495 132.9 17.6 241 131.0 16.5 317 132.8 15.3 426 132.5 19.3 304 129.4 17.3 0.043
Neutrophilic granulocyte count ( ×109/l) 491 5.2 2.4 239 4.9 2.2 318 5.2 2.3 422 5.2 2.6 304 4.9 2.0 0.112
WBC ( ×109/l) 495 7.6 2.6 242 7.4 2.8 318 7.6 2.7 428 7.8 2.8 305 7.5 2.4 0.601
Platelet count ( ×1010/l) 493 24.9 8.0 241 25.6 9.4 317 25.9 8.6 424 25.0 25.8 304 24.8 8.2 0.213
Tumor stage and histology (%)                 
Stage 4 478 92.5% 215 86.7% 273 84.8% 395 87.8% 248 80.4% <0.001
Adenocarcinoma type 512 99.0% 241 97.2% 313 97.2% 440 97.8% 307 99.3% 0.272
Number of metastasis site (%)                 
1 250 48.4% 107 43.2% 143 44.4% 100 22.2% 153 49.7% 0.513
2 123 23.8% 49 19.8% 70 21.7% 211 46.9% 66 21.2% 0.758
3 or above 64 12.4% 20 8.1% 32 9.9% 100 22.2% 22 7.2% 0.083
Location of metastasis (%)                 
Brain 84 16.3% 49 19.8% 58 18.0% 68 15.1% 42 13.7% 0.289
Bone 200 38.7% 87 35.1% 98 30.4% 162 36.0% 109 35.3% 0.199
Liver 48 9.3% 23 9.3% 29 9.0% 32 7.1% 24 7.8% 0.729
Pleural 128 24.8% 28 11.3% 50 15.5% 80 17.8% 45 14.7% <0.001
Platinum agent used in doublet                 
Cisplatin 400 77.4% 111 44.7% 251 77.8% 385 85.6% 272 87.9% <0.001
Carboplatin 117 22.6% 137 55.3% 71 22.2% 65 14.4% 37 12.1% <0.001
Hematological AE management                 
G-CSF 172 33.3% 108 43.5% 167 51.9% 209 46.4% 215 69.6% <0.001
EPO 5 1.0% 1 0.3% 0 0.0% 9 2.0% 3 1.0% 0.066
IL-11 16 3.1% 5 1.9% 3 0.9% 44 9.8% 39 12.6% <0.001
TPO 17 3.3% 2 0.6% 0 0.0% 9 2.0% 3 1.0% 0.003
RBC 1 0.2% 0 0.0% 0 0.0% 5 1.1% 8 2.6% <0.001
Platelet 1 0.2% 1 0.3% 0 0.0% 3 0.7% 4 1.3% 0.148
  1. AE, adverse event; STDEV, standard deviation; BMI, body mass index; BSA, body surface area; ECOG, Eastern Cooperative Oncology Group; WBC, white blood cell; G-CSF, granulocyte colony-stimulating factor; EPO, erythropoietin; IL-11, interleukin 11; TPO, thrombopoietin; RBC, red blood cell. *: P values less than 0.05 were in bold to indicate significant differences.